Evidence map›Paper›PMID 40518017›Full record

ArticleJournal of virological methods2025

Illumina MiSeq and iSeq platforms yield comparable results for viral genomic sequencing.

Darlene D Wagner, Grace Nabakooza, Nehalraza Momin, Rachel L Marine

Abstract readComparative Study
In one paragraph

Article in Journal of virological methods, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Darlene D WagnerEagle Global Scientific LLC, contracting agency to the Centers for Disease Control and Prevention, Atlanta, Georgia. Electronic address: darlingtonwagner@gmail.com.
Grace NabakoozaEagle Global Scientific LLC, contracting agency to the Centers for Disease Control and Prevention, Atlanta, Georgia.
Nehalraza MominEagle Global Scientific LLC, contracting agency to the Centers for Disease Control and Prevention, Atlanta, Georgia.
Rachel L MarineDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Funding

CDC HHSIntramural CDC HHS CC999999
6 · The paper itself

Abstract

Illumina MiSeq and iSeq are widely used short-read next-generation sequencing (NGS) platforms. The MiSeq instrument is specialized for mid-range throughput, while the iSeq instrument has lower throughput but is less expensive and simpler to operate. Several studies have compared Illumina platforms for sequencing of a variety of specimen types, but very few have quantified differences in sequencing quality, particularly for viruses. This study compared read quality, single nucleotide polymorphism (SNP) calling, and assembly metrics for SARS-CoV-2, norovirus, and poliovirus samples sequenced on both platforms. MiSeq and iSeq trimmed reads exhibited equivalent percentage of bases ≥ Q30 (% ≥ Q30) and equivalent reference mapping percentages. SNP concordance rates between the two platforms were 41 out of 43 (95.3 %) for SARS-CoV-2, 1628 out of 1633 (99.7 %) for norovirus, and 9 out of 11 (81.8 %) for poliovirus. Within each of the three virus groups, MiSeq and iSeq assemblies had equivalent N50 and maximum contig lengths. Despite platform-specific differences in the sequencing chemistry and flow cell design, MiSeq and iSeq offered comparable data quality, indicating that using either platform should produce concordant results for viral genomic sequencing.

Indexed as

Genome, ViralHigh-Throughput Nucleotide SequencingNorovirusPoliovirusSARS-CoV-2COVID-19HumansPolymorphism, Single NucleotideCost ComparisonIlluminaNext-generation sequencing (NGS)RNA virusesSequencing Quality

Identifiers

PMID40518017
PMCPMC13647441

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.